Open Access
Prognostic significance and targeting of HER family in colorectal cancer
Said Abdullah Khelwatty1,Sharadah Essapen2,Alan Michael Seddon1,Helmout Modjtahedi1,*
School of Life Sciences, Kingston University London, Kingston, UK
St Luke's Cancer Centre, Royal Surrey County NHS Foundation Trust, Guildford, Surrey, UK
DOI: 10.2741/4110 Volume 18 Issue 2, pp.394-421
Published: 01 January 2013
*Corresponding Author(s):  
Helmout Modjtahedi

Colorectal cancer is one of the leading causes of cancer deaths. At present, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) cetuximab and panitumumab and anti-vascular endothelial growth factor (VEGF) mAb bevacizumab have been incorporated into treatment paradigms for patients with refractory metastatic colorectal cancer. However, many patients simply do not respond to these treatments or eventually acquire resistance following a short course therapy. In this article, we review the literature for studies on the expression patterns, prognostic significance and predictive value of HER (also called erbB) family members and other factors for response to therapy with the HER inhibitors in colorectal cancer. We discuss some of the advances, challenges as well as future opportunities for more effective targeting of the HER receptors using a cocktail of HER inhibitors (e.g. dual and pan HER TKIs, monospecific or bispecific antibodies) in combination with other therapeutic interventions.

Key words

EGFR, HER-2, HER-3, HER-4, Small Molecule Tyrosine Kinsase, Monoclonal Antibody, Colorectal Cancer, Review

Share and Cite
Said Abdullah Khelwatty, Sharadah Essapen, Alan Michael Seddon, Helmout Modjtahedi. Prognostic significance and targeting of HER family in colorectal cancer. Frontiers in Bioscience-Landmark. 2013. 18(2); 394-421.